MA02.07 Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial

医学 消炎药 可视模拟标度 随机对照试验 肺癌 临床终点 内科学 生活质量(医疗保健) 书呆子 性能状态 麻醉 胃肠病学 癌症 化疗 止吐药 疾病 格尔德 护理部 回流
作者
K. Prabhash,Vanita Noronha,Atanu Bhattacharjee,VijayM Patil,Amit Joshi,S. Shah,Srinivasaraghavan Kannan,S. Ishi
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:13 (10): S360-S360 被引量:1
标识
DOI:10.1016/j.jtho.2018.08.327
摘要

Cough is a distressing symptom in patients with lung cancer. Effective management of cough leads to improvement in quality of life (QoL) and optimal palliative care. Aprepitant, a centrally acting neurokinin-1 inhibitor, has been shown in a pilot study to significantly decrease the cough frequency. A randomized open-label study in patients with advanced lung cancer with cough for over 2 weeks despite therapy with a cough suppressant, with an ECOG performance status 0 to 2. Patients were randomized 1: 1 to Arm A: aprepitant 125 mg orally on day 1, followed by 80 mg orally on days 2 to 7 along with physician’s choice of antitussive therapy. Patients on Arm B received physician’s choice of antitussive therapy. Patients were evaluated at baseline and then on days 3, 7, 9 and 12. Primary efficacy endpoint was subjective improvement in cough, measured with the Visual Analog Scale (VAS) and the Manchester Cough in Lung Cancer Scale (MCLCS). Secondary endpoints included toxicity and QoL, measured by the EORTC QLQ-C30 and LC13. The trial was approved by the` institutional IEC and registered with (CTRI/2017/05/008691). Between June 2017 and June 2018, 128 patients were randomized: 64 to each arm. The median age was 53 yrs, 65% male, 64% never-smokers, 82% had adenocarcinoma. 88% had Stage IV disease; 80% had PS 1 and 20% PS 2. The median duration of cough was 90 days. VAS scores at baseline and day 9 was 67.93, 38.50 in Arm A and 63.15, 48.57 Arm B , with p<0.001 and the MCLCS scores at baseline and day 9 was 30.03, 22.32 in Arm A and 27.53, 23.80 Arm B , with p<0.001. Overall, there was no significant difference in the QoL scores in patients in the two arms, however there was a significant improvement in the cough-specific QoL domain in the patients on the aprepitant arm, p=0.017. There was no increase in the grade 3 and higher adverse events in the patients on the aprepitant arm. Aprepitant led to a significant improvement in cough in patients with advanced lung cancer, with no increase in severe side-effects. Aprepitant should be considered as one of the treatment options for cough in lung cancer patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健应助pokikiii采纳,获得10
刚刚
bathygobius完成签到,获得积分10
1秒前
orixero应助axt采纳,获得10
1秒前
1秒前
1秒前
张豪杰完成签到 ,获得积分10
2秒前
丘比特应助笔墨留香采纳,获得10
2秒前
2秒前
2秒前
抄手完成签到,获得积分10
3秒前
surge发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
SciGPT应助尔尔采纳,获得30
4秒前
酷波er应助你晖哥采纳,获得10
5秒前
5秒前
量子星尘发布了新的文献求助10
5秒前
yuhang发布了新的文献求助10
6秒前
Lucas应助申小萌采纳,获得30
6秒前
6秒前
在水一方应助科研通管家采纳,获得10
7秒前
7秒前
FashionBoy应助一方通行采纳,获得10
7秒前
柯一一应助科研通管家采纳,获得10
7秒前
我是老大应助科研通管家采纳,获得10
7秒前
完美世界应助科研通管家采纳,获得10
7秒前
lily发布了新的文献求助10
7秒前
思源应助科研通管家采纳,获得10
7秒前
打打应助科研通管家采纳,获得10
7秒前
科研通AI2S应助科研通管家采纳,获得10
7秒前
在水一方应助科研通管家采纳,获得10
7秒前
FashionBoy应助科研通管家采纳,获得10
7秒前
Lucas应助科研通管家采纳,获得10
8秒前
8秒前
YamDaamCaa应助科研通管家采纳,获得30
8秒前
Ting应助科研通管家采纳,获得10
8秒前
柯一一应助科研通管家采纳,获得10
8秒前
lishuai发布了新的文献求助10
8秒前
科研通AI2S应助科研通管家采纳,获得10
8秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975250
求助须知:如何正确求助?哪些是违规求助? 3519625
关于积分的说明 11199055
捐赠科研通 3255962
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877358
科研通“疑难数据库(出版商)”最低求助积分说明 806298